GNS Healthcare, Inc. announced today that Harvard Medical School has licensed its REFS™ (Reverse Engineering and Forward Simulation) Big Data analytics platform. Under the five-year license, Harvard researchers will use REFS™ to characterize and understand signaling and transcriptional events in biological systems. Financial terms of the agreement were not disclosed.

“Reverse engineering is a key challenge for systems biology,” said Marc Kirschner, Professor and Chair of the Department of Systems Biology at Harvard Medical School. “Achieving a synergy between the design of experiments and reverse engineering methods will be defining for how we understand biological mechanism in the next century.”

CAMBRIDGE, Mass. – April 18, 2013 – GNS Healthcare today announced a partnership with the Centers for Medicare & Medicaid Services (CMS) and Health Services Advisory Group (HSAG) to assess CMS’ quality measures. GNS will use its cutting-edge REFS™ (Reverse Engineering and Forward Simulation) Big Data analytics and machine learning platform to help determine the impact that quality measures have on the quality of care delivered to patients.

CMS quality measures are collected and reported with the goal of …

Industry and Patient Groups Join Forces to Form an Alliance to Accelerate Drug Development

CAMBRIDGE, Mass. – March 4, 2013 – GNS Healthcare today announced that it has joined in the formation of Orion Bionetworks. This unique alliance will work to transform our understanding of and accelerate the drug development process for a wide variety of diseases, beginning with multiple sclerosis (MS). Using patient data from alliance members Accelerated Cure Project for Multiple Sclerosis, the Institute for Neurosciences …

Industry and Patient Groups Join Forces to Form an Alliance to Accelerate Drug Development

BOSTON – March 4, 2013 – Today we announce the launch of Orion Bionetworks, a multi-institution cooperative non-profit alliance that is unlocking the power of shared data and predictive modeling to help transform our understanding of diseases such as multiple sclerosis (MS) and accelerate the search for cures. Alliance partners include leading organizations in patient care, computational modeling, translational research, and patient advocacy: Accelerated Cure Project …

CAMBRIDGE, Mass., Nov. 12, 2012 — GNS Healthcare, Inc., the leading healthcare data analytics company focused on enabling personalized medicine to improve human health, today announced that Colin Hill, Chief Executive Officer and Co-Founder, is scheduled to present at the Lazard Capital Markets 9th Annual Healthcare Conference on Tuesday, November 13, 2012 at 1:30 p.m. (ET) at The Pierre Hotel in New York, New York.

About GNS Healthcare

GNS Healthcare is a ‘Big Data’ analytics company that has developed a …

Collaborators Will Unravel Underlying Biology of Multiple Myeloma and Advance Discovery of New Treatments

CAMBRIDGE, MA, BOSTON and NEW YORK, November 8, 2012 – GNS Healthcare, Inc. (GNS), the leading healthcare data analytics company focused on enabling personalized medicine to improve human health, today announced that it has entered into a collaboration with Dana-Farber Cancer Institute (Dana-Farber) and Mount Sinai School of Medicine (Mount Sinai) to create a data-driven computer model of multiple myeloma, the second most common blood …

New CSO to help company develop enhanced analytics offerings further enabling data-driven development of precision medicines

CAMBRIDGE, Mass., October 11, 2012 – GNS Healthcare, Inc. (GNS), the leading Big Data analytics company focused on enabling personalized medicine to improve human health, today announced the expansion of its senior management team, adding Hans Winkler, Ph.D., as Chief Scientific Officer. Dr. Winkler will promote the development of the Company’s intellectual property, building out product infrastructure and fostering the overall scientific strategy for the Company’s product …

Models Will Identify Members’ Risk and the Most Effective Interventions Before More Severe Health Issues Arise

CAMBRIDGE, MA, September 26, 2012 – GNS Healthcare today announced a new program with Aetna (NYSE: AET) that aims to treat and prevent metabolic syndrome. The syndrome significantly increases the risk of developing heart disease, stroke and diabetes. GNS’ supercomputer-driven REFS™ (Reverse Engineering and Forward Simulation) platform will help identify members at risk for this disorder earlier, evaluate the members who already have the …

GNS Will Use Big Data Analytics Platform to Build Novel Computer Models to Better Predict Clinical Trial Success and Identify Responsive Patients

CAMBRIDGE, MA, September 19, 2012 – GNS Healthcare, Inc. (GNS), the leading healthcare data analytics company focused on enabling personalized medicine to improve human health, today announced that it has entered into a collaboration with Covance, one of the world’s largest and most comprehensive contract research organizations. The collaboration is focused on developing novel data-driven models that …

Aetna announced a collaboration between its Innovation Labs and GNS Healthcare aimed at leveraging big data to achieve better outcomes for those at risk for metabolic syndrome and heart disease.…